Pegylated Interferon-Alpha-2A
Fallopian Tube Carcinoma
The University of Texas Health Science Center at San AntonioPhase 2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
14 Active assets in the Fallopian Tube Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CIS-DIAMMINEDICHLOROPLATINUM II The Netherlands Cancer Institute | Phase 3 | BB |
Cyclophosphamide Beijing Biotech | Phase 2 | BB |
Carboplatin University of Washington | Phase 3 | BB |
Inno-206 Advenchen Laboratories, LLC | Phase 3 | BB |
Olaparib National Cancer Institute (NCI) | Phase 2 | B |
View all 50 →
Same molecule, other indications
Pegylated Interferon-Alpha-2A is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →